Lylly's Actos outruns Avandia sales due to drug safety problems.

The sales of Actos, a rival anti-diabetic drug for type 2 diabetes developed and marketed by Lilly, showed far surpassing to Avandia by 24% increase in June over the previous month probably due to the recent serious reports on the increased risk of cardiovascular disease on the New England Journal of Medicine (NEJM) published in May this year.

Avandia sales in June dropped by 13% down from ...